Recursion Pharmaceuticals, Inc.

US$3.52As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:RXRXHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (33.45%)
Div yield —
ROE (48.72%)
Biotechnology
Beta (5Y) 1.15
PE TTM —
TSR TTM (36.23%)
Mkt cap US$2.194B
ROIC (29.68%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$3.90
10.77%
(53.68%)
Buy 7|1|2|9|6
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.03
0.03
0.03
0.03
5.12%
10.89%
12.58%
17.56%
Revenue$M
126.6
134.1
133.5
135.2
4.02%
8.77%
11.39%
9.11%
Peers (US$2.194B)
Cap (US$)
PE
2.208B
—
2.187B
—
Capital
TTM
5Y
10Y
Leveragex
0.677
0.100
0.073
EBIT/Intx
0.332
0.375
0.287
Own earn%
(19.89)
84.26
59.76
Sh yield%
12.56
64.21
61.16
Owners
Insiders/Inst%
13.64
79.77
Short interest%
4.42
SBC / revenue%
2.62
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
15
Op margin range%
14–23
$1 testx
—
Incr. ROIC%
9